NCT01277107CompletedPhase 2
Double Blind, Polysomnographic, Two-Way Crossover Study To Compere The Efficacy Of Gastric Retentive Zaleplon (Zaleplon AP) To Placebo In Subjects With Insomnia Characterized By Both Difficulty In Falling Asleep And Staying Asleep
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Intec Pharma Ltd.
- Enrollment
- 83
- Locations
- 6
- Primary Endpoint
- To determine the effect of dual release Zaleplon (Zaleplon AP) on Total Sleep Time (TST)
Study Overview
Brief Summary
This is a multi center, double blind placebo controlled, two-way crossover study in patients with Insomnia suffering from difficulty in falling asleep and staying asleep. This study intends to assess the efficacy of Zaleplon AP in improving sleep parameters, comparing to placebo.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Subjects between the ages of 18 and 65 years of age
- •Subjects that meet DSM IV diagnostic criteria for Primary Insomnia
- •Subjects that report a time in bed ≥6.5 and ≤9 hours
- •Subjects that report on a one week sleep diary (on at least 3 of 7 nights) TST ≤6.5 hours
- •Subjects that report on a one week sleep diary (on at least 3 of 7 nights)Wake time after sleep >1.0 hour
- •Subjects that report on a one week sleep diary (on at least 3 of 7 nights) ≥30 minutes time to sleep onset
- •On two nights of PSG screening a mean WASO of ≥60 minutes with neither night less than 45 minutes
- •On two nights of PSG screening a mean LPS of ≥20 minutes with neither night less than 15 minutes
- •On two nights of PSG screening a TST of ≤6.5 hours on each of the two nights
- •Body mass index of 18 - 34 inclusive
- •Subjects that report a median habitual bedtime between 9:00pm (21:00 hours) and 12:00am (00:00) on a one week sleep diary (based on 3 or more nights).
Exclusion Criteria
- •Participation in another drug clinical trial within 1 month prior to first screening diary day (calculated from the previous study's last dosing date).
- •On screening PSG night 1 an AHI >10 (apnea hypopnea index)
- •On screening PSG night 1 a PLMAI ≥10 (periodic limb movements with arousal)
- •Subject has a circadian rhythm disorder including shift work or the need to travel ≥3 time zones during the course of the study
- •Subject has any other sleep disorder (e.g. Restless Legs Syndrome )
- •Use of any drug known to effect sleep or wake functions within 5 half lives of the drug or two weeks, whichever comes first.
- •Subject with a history (past year) of alcohol or substance abuse
- •Subject that needs to smoke during the sleep period time
- •Subject that reports habitual napping (more than 3 times per week)
- •Subject has currently or a significant history of seizures, sleep apnea or restless leg syndrome or other sleep disorders which, in the opinion of the investigator responsible, contraindicates his/her participation
- •Subjects with a recent history of clinically defined GERD, peptic ulcer or any gastrointestinal surgery other than appendectomy or herniotomy which, in the opinion of the investigator responsible, contraindicates his/her participation
- •Subject with any gastrointestinal disorder likely to influence drug absorption, or with any history of inflammatory bowel disease, intestinal obstruction, irritable bowel syndrome, severe gastrointestinal narrowing, or frequent nausea or emesis, regardless of etiology which, in the opinion of the investigator responsible, contraindicates his/her participation
- •Subjects suffering from any Axis 1 Psychiatric Disorder that in the opinion of the investigator responsible may interfere with full participation
- •Subject has significant history of cardiac, pulmonary, hepatic or renal disease or other condition or any major complication/illness which, in the opinion of the investigator responsible, contraindicates his/her participation.
- •The subject has any clinically important abnormal finding as determined by a medical history, physical examination, electrocardiogram, or clinical laboratory tests, as determined by the investigator
- •Subject is taking CNS-active drugs (including herbal products with CNS effects), known to affect the sleep/wake cycle including but not limited to anxiolytic, hypnotics, antidepressants, sedating H1 antihistamines, systemic steroids, anticonvulsants, narcotic analgesics, respiratory stimulants respiratory decongestants, OTC and prescription diet aids, OTC and prescription stimulants, St. John's Wort, and melatonin.
- •Females who are pregnant or nursing.
Arms & Interventions
Zaleplon AP formulation
Experimental
Gastric Retentive Dual Release Zaleplon (Zaleplon AP)
Intervention: Zaleplon AP formulation (Drug)
Placebo
Placebo Comparator
Identical placebo capsule
Intervention: Placebo capsule (Drug)
Outcomes
Primary Outcomes
To determine the effect of dual release Zaleplon (Zaleplon AP) on Total Sleep Time (TST)
Time Frame: Polysomnography tests for 2 consecutive nights at each treatment arm
The change from baseline on the mean of drug nights 1 and 2 relative to placebo.
Secondary Outcomes
- To determine the efficacy of Zaleplon AP on Latency to Persistent Sleep (LPS)(Polysomnography tests for 2 consecutive nights at each treatment arm)
- To determine the efficacy of Zaleplon AP on Wake time After Sleep Onset (WASO)(Polysomnography tests for 2 consecutive nights at each treatment arm)
- To evaluate the presence of any residual effects using the digital symbol substitution test (DSST) and a memory test(2 consecutive mornings at each treatment arm)
Investigators
Study Sites (6)
Loading locations...
Similar Trials
Terminated
Phase 1
Safety Study of AMG 811 in Subjects With Discoid Lupus ErythematosusCutaneous LupusDiscoid LupusLupusSystemic Lupus ErythematosusNCT01164917Amgen16
Not yet recruiting
Not Applicable
Crossover Study of the PD of ENA-001 and hypoxia.Respiratory impairmentNL-OMON24789Enalare Therapeutics12
Terminated
Not Applicable
G-PUR® for Reduced Dietary Fumonisin BioavailabilityReduction of Dietary Fumonisin BioavailabilityNCT04494178Glock Health, Science and Research GmbH7
Completed
Phase 2
Efficacy and Safety Study in Subjects With AsthmaAsthmaNCT00980200GlaxoSmithKline75
Completed
Not Applicable
The Ketogenic Diet in the Treatment of Alzheimer's DiseaseAlzheimer DiseaseNCT06681948Capital Medical University32